Macquarie Group LTD Zymeworks Inc. Transaction History

Macquarie Group LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.7 $4,198 - $6,706	-871 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$29.83 - $56.81 $647,012 - $1.23 Million	-21,690 Reduced 96.14%	871 $28,000
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $66,543 - $93,537	-1,701 Reduced 7.01%	22,561 $1.07 Million
Q3 2020 Nov 13, 2020	SELL	$29.21 - $46.58 $25,120 - $40,058	-860 Reduced 3.42%	24,262 $1.13 Million
Q2 2020 Aug 11, 2020	BUY	$33.67 - $40.0 $167,508 - $199,000	4,975 Added 24.69%	25,122 $906,000
Q1 2020 May 15, 2020	BUY	$24.28 - $49.8 $489,169 - $1 Million	20,147 New	20,147 $715,000
Q1 2019 May 15, 2019	SELL	$14.02 - $16.74 $18,310 - $21,862	-1,306 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$10.95 - $15.44 $153 - $216	-14 Reduced 1.06%	1,306 $19,000
Q3 2018 Nov 15, 2018	BUY	$12.21 - $16.61 $16,117 - $21,925	1,320 New	1,320 $21,000
Q1 2018 May 11, 2018	SELL	$7.93 - $13.41 $4,758 - $8,046	-600 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$6.87 - $9.19 $4,122 - $5,514	600	600 $5,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.